Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLK inhibitor (Belfer Neurodegeneration Consortium)
- Development stage
- Preclinical
- Lead developer
- Neurodegeneration Consortium
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This dual leucine zipper kinase (DLK) inhibitor is a small-molecule therapeutic candidate developed by the Belfer Neurodegeneration Consortium at MD Anderson Cancer Center. DLK is a key regulator of the neuronal stress response; its activation leads to axonal degeneration and neuronal apoptosis in various neurodegenerative conditions. By inhibiting DLK, this compound aims to preserve neuronal integrity and prevent the cognitive and sensory deficits associated with neurodegeneration. The program is currently in preclinical development, targeting a range of conditions including Alzheimer's disease, chemotherapy-induced peripheral neuropathy (CIPN), and chemotherapy-related cognitive impairment, commonly referred to as chemobrain.
- Other names
- dual leucine zipper kinase inhibitorDLK inhibitor
02
Targets
MAP3K12 (Mitogen-activated protein kinase kinase kinase 12)MAP3K13 (Mitogen-activated protein kinase kinase kinase 13)MEK5 (Mitogen-Activated Protein Kinase Kinase 5)NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on DLK inhibitor (Belfer Neurodegeneration Consortium).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLK inhibitor (Belfer Neurodegeneration Consortium).